Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03239353
Other study ID # UAP008C001
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date October 20, 2017
Est. completion date June 20, 2018

Study information

Verified date June 2018
Source Aucta Pharmaceuticals, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1, randomized, parallel-group, single-center study in healthy adult subjects. The study will be conducted in two parts sequentially:

Part 1 is an open-label, two-arm, active-controlled design to evaluate the PK and safety of single oral dose of ETV XR tablet (1.5 mg) in healthy subjects. Part 1 will consist of 16 healthy subjects.

Part 2 is a double-blind, three-arm, placebo-controlled design to evaluate the PK and safety of higher oral doses of ETV XR tablet (3 mg and 6 mg) in healthy subjects. Part 2 will consist of 24 healthy subjects.


Recruitment information / eligibility

Status Completed
Enrollment 40
Est. completion date June 20, 2018
Est. primary completion date May 29, 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion criteria:

Subjects will be considered for enrollment in the study if they meet all of the inclusion criteria and none of the exclusion criteria.

1. Male or female aged between 18 and 55 years (inclusive). Body weight = 50 kg for males, and =45 kg for females and Body Mass Index (BMI) between 18 and 28 kg/m2 (inclusive), BMI(kg/m2) = body weight(kg)/{height(m)}2;

2. Ability to fully understand the purpose, characteristic, method and the possible adverse effects of the trial, and voluntarily signed Informed Consent obtained before any trial-related procedures are performed;

3. Ability to comply with the requirements of this trial protocol, including refrain from strenuous exercise/activity 3 days prior to Day -1 (admission) and for 3 days prior to the Day 8, Day 15 and the final follow-up visit on Day 22through the duration of the study

4. Have a creatinine clearance (CLCr) = 80 mL/min;

5. Male subjects and female subjects of child bearing potential must be willing to practice effective contraception during the study and been willing and able to continue contraception for 90 days after their dose of the study treatment;

6. Male subjects must refrain from sperm donation from Day -1 through completion of the study and continuing for at least 90 days from the date of last dose of study drug;

7. Subjects must refrain from blood donation from Screening through completion of the study and continuing for at least 30 days from date of last dose of study drug;

8. AST, ALT and bilirubin = 1.5xULN (isolated bilirubin > 1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%);

9. Must, in the opinion of the Investigator, be in good health based upon medical history, physical examination (including vital signs), and screening laboratory evaluations (hematology, chemistry, and urinalysis must fall within the normal range of the central laboratory reference ranges unless the results have been determined by the Investigator to have no clinical significance).

Exclusion criteria:

A subject meeting any of the following criteria will be excluded from the study:

1. Current or a history of any clinically significant medical illness or medical disorders the investigator considers should exclude including (but not limited to) neurological disease, cardiovascular disease, hepatic or renal disease, gastrointestinal tract disease (such as dysphagia, gastrointestinal ulcers), respiratory disease, metabolism, skeletal system diseases or other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs;

2. Has a positive result from serology examination for hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV);

3. There are drug-dependent or drug abuse history, or urine drug abuse screening positive;

4. Subject smoked more than 5 cigarettes or other tobacco or nicotine-containing products within 1 month prior to dosing and is unwilling to abstain from smoking for 48 hours prior to check-in (Day -1)ing, for the duration of the confinement period and at each follow-up visit;

5. Has used an alcohol consumption of more than 14 units of alcohol per week (1 unit of alcohol is equivalent to 360 mL of beer or 45 mL of spirits with 40 % of alcohol or 150 mL of wine) within 6 months prior to screening or taking products containing alcohol 48 hours prior to IMP administration;

6. Participated in any drug or medical device clinical trial within 3 months prior to screening;

7. Pregnant or breastfeeding women or pregnancy testing is positive;

8. Have taken any prescription medications, over-the-counter medications, supplements or herbal products within 14 days, or 5 half-lives (whichever is longer), of study drug dosing, with the exception of paracetamol and hormonal contraceptive medications, unless in the opinion of the Investigator and/or Medical Monitor that the substance would not have any material impact on participant safety or the quality of study data;

9. Donated blood greater than 400 mL or significant blood loss equivalent to 400 mL or received blood transfusion within 3 months of screening; Or donated blood greater than 200 ml or significant blood loss equivalent to 200 mL within 1 months prior to screening;

10. Has infectious diseases within four weeks at screening (in the opinion of the investigator would pose a risk for participation in this study), severe trauma, or a history of major surgery within 3 months;

11. Cannot tolerate venepuncture or cannulation;

12. Consumption of grapefruit, grapefruit juice, cranberries, or products containing Seville oranges (fruit juices, marmalade, jam, etc) within 7 days prior to study drug dosing; consumption of caffeine-containing products within 48 hours of study drug dosing;

13. Have been vaccinated within 90 days of study dosing, with the exception of licensed intranasal or intramuscular influenza vaccine = 14 days prior to dosing.

14. Have severe multiple allergies and / or severe allergies (including latex / heparin allergy) history, or has hypersensitivity or significant intolerance to prescription drugs or over-the-counter drugs or food;

15. Subjects who, in the opinion of the Investigator, should not participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Entecavir
Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.

Locations

Country Name City State
Australia Linear Clinical Research Ltd Nedlands Western Australia

Sponsors (1)

Lead Sponsor Collaborator
Aucta Pharmaceuticals, Inc

Country where clinical trial is conducted

Australia, 

Outcome

Type Measure Description Time frame Safety issue
Primary To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses in healthy subjects. Peak Plasma Concentration(Cmax) 22 days
Primary To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses Area under the plasma concentration versus time curve (AUC) 22 days
Primary To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses peak time (Tmax) 22 days
Primary To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses Relative bioavailability (Frelative) 22 days
Primary To characterize the Pharmacokinetics (PK) of ETV XR tablet after single oral doses half life (t1/2) 22 days
Secondary To assess ETV XR tablet in healthy subjects. adverse events 22 days
Secondary To assess ETV XR tablet in healthy subjects. laboratory abnormalities 22 day
Secondary To assess ETV XR tablet in healthy subjects. vital signs 22 days
Secondary To assess ETV XR tablet in healthy subjects. 12-lead electrocardiograms (ECGs) 22 days
Secondary To evaluate the dose linearity of ETV XR tablet 1.5mg, 3mg and 6mg PK linearity 60 days
See also
  Status Clinical Trial Phase
Completed NCT05442437 - Clinical Study of hUC-MSCs Treating Decompensated Liver Cirrhosis With HBV Early Phase 1
Not yet recruiting NCT05951751 - The TRIple Elimination Model Of Mother-to-child Transmission Program (TRI-MOM) N/A
Completed NCT04519710 - Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies N/A
Recruiting NCT04562051 - Stratified vs Routine Prophylaxis in Living Kidney Transplantation From HBsAg+ Donors to HBsAg- Recipients
Recruiting NCT04683341 - Tenofovir Alafenamide in HBV Related Decompensated Liver Phase 4
Active, not recruiting NCT02344680 - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed NCT02044068 - Hepatitis B Virus Vertical Transmission From HIV-HBV Co-infected Women N/A
Recruiting NCT04904835 - Access HBV Assays - European Union (EU) Clinical Trial Protocol -
Terminated NCT04059198 - Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus Phase 2
Not yet recruiting NCT05293158 - Impact of Hepatitis B Immunoglobulins in Patients With Chronic Hepatitis B on Hepatocellular Carcinoma - a Proof of Concept Study N/A
Not yet recruiting NCT05028322 - Evaluation of Intradermal Hepatitis B Vaccine After IMIQUIMOD's Application, in Cirrhotics Who Did Not Respond to the Usual Vaccine Regimen Phase 2
Not yet recruiting NCT01556815 - Sorafenib Combined With Transarterial Chemoembolization in Treating HBV-infected Patients With Intermediate Hepatocellular Carcinoma Phase 2
Completed NCT02312531 - Prevention for Mother-to-infant Transmission of HBV N/A
Recruiting NCT05786859 - The Efficacy and Safety of Rifaximin Treatment Early Phase 1
Not yet recruiting NCT06307808 - Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
Completed NCT03149627 - Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults
Recruiting NCT04886336 - The Impact of Tenofovir Alafenamide on Profiles of Body Weight and Metabolic Features in Chronic Hepatitis B Patients.
Recruiting NCT04568265 - A Clinical Study of APG-1387 in Combination With Entecavir in Patients With Chronic Hepatitis B Phase 2
Terminated NCT02826018 - A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection Phase 1
Completed NCT01970254 - Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy